Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 572

Sort by

Sort Order Select

Journal Articles

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Dasom Lee, MD, Hannah H Asghari, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3894.

https://doi.org/10.1182/blood-2019-127701

Published: 2019

Journal Articles

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Kwanza Price, MPH, Zhun Cao, PhD, Craig Lipkin, Scott Robinson, Deborah Ann Profant, PhD

Blood (2019) 134 (Supplement_1): 2213.

https://doi.org/10.1182/blood-2019-127075

Published: 2019

Journal Articles

Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia

Hassan Awada, Ashwin Kishtagari, MBBS, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Manja Meggendorfer, PhD, Anjali S. Advani, MD, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Torsten Haferlach, MD, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2720.

https://doi.org/10.1182/blood-2019-131301

Published: 2019

Journal Articles

Treatment Outcome and a Practical 10-Point Prognostic Index in Adult Patients with Non-M3 Acute Myeloid Leukemia: A Retrospective, Multicenter Study in Malaysia

Tze Shin Leong, MBBS,MRCP,MSc, Sen Mui Tan, Lee Ping Chew, Tee Chuan Ong, Siew Lian Chong, Kar Ying Yong, Siong Leng Hon, Syazarin Fidhora Nasution, Ching Tiong Ko, Vanusha Devaraja, Andy Sing Ong Tang, Tsen Chuen Jerome Tan, Ngee Siang Lau, Sharifah Shahnaz Syed Abd Kadir, Veena Selvaratnam, Yee Yee Yap, Bee Sun Lee, William Kian Boon Law, Jameela Sathar

Blood (2019) 134 (Supplement_1): 2606.

https://doi.org/10.1182/blood-2019-126656

Published: 2019

Journal Articles

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

Muhned Alhumaid, MD, Georgina S Daher-Reyes, MD, Wilson Lam, MD, Arjun Law, MDDM, Tracy Murphy, MDFRCP,FRCPath, Caroline J McNamara, MBBS, Gil Yerushalmi, Aaron D Schimmer, MD PhD, Andre C. Schuh, MD, Dawn Maze, MDFRCPC,MSc, Eshetu G Atenafu, M.Sc., P.Stat, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Hassan Sibai, MBBS

Blood (2019) 134 (Supplement_1): 2609.

https://doi.org/10.1182/blood-2019-125449

Published: 2019

Journal Articles

Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count

Xueyan Chen, MD, Megan Othus, PhD, Brent L Wood, MD PhD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 2692.

https://doi.org/10.1182/blood-2019-124977

Published: 2019

Journal Articles

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Katherine Tarlock, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Yi-Cheng Wang, Robert B. Gerbing, Laura Pardo, Fangyan Dai, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Jessica A. Pollard, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 2699.

https://doi.org/10.1182/blood-2019-127100

Published: 2019

Journal Articles

PKC-Epsilon Overexpression Is Associated with Poor Outcomes in AML and Promotes Chemoresistance and Hematopoietic Stem Cell Quiescence

Rachael Louise Nicholson, BSc, Steven Knapper, DM, Alex Tonks, PhD, Richard L Darley, PhD

Blood (2019) 134 (Supplement_1): 2704.

https://doi.org/10.1182/blood-2019-128184

Published: 2019

Journal Articles

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Blood (2019) 134 (Supplement_1): 2612.

https://doi.org/10.1182/blood-2019-129153

Published: 2019

Journal Articles

The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia

Chao-Hung Wei, MD, Cheng-Hong Tsai, MD, M.Sc., Jih-Luh Tang, MD, PhD, Yuan-Yeh Kuo, PhD, Feng-Ming Tien, MD, M.Sc, Chien-Chin Lin, MD, Mei-Hsuan Tseng, M.Sc., Yen-Ling Peng, Ming-Chih Liu, Chia-Wen Liu, Ming Yao, MD, Liang-In Lin, PhD, Wen-Chien Chou, MD, PhD, Chien-Yu Chen, PhD, Hsin-An Hou, Hwei-Fang Tien, MD, PhD

Blood (2019) 134 (Supplement_1): 2705.

https://doi.org/10.1182/blood-2019-124657

Published: 2019

Journal Articles

Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival

Constance Baer, PhD, Wencke Walter, PhD, Anna Stengel, PhD, Stephan Hutter, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 2735.

https://doi.org/10.1182/blood-2019-128234

Published: 2019

Journal Articles

Effectiveness and Survival of 4 Courses of Chemotheray in 321 Children with Acute Myeloid Leukemia in China: A Multicenter, Nonrandomized Clinical Study

Zheng Yong Zhi, MD, Jian Li, MD, Xiaoqin Feng, Mincui Zheng, Chunfu Li, MD, Honggui Xu, Yingyi He, MD& PhD, Huirong Mai, Xiangling He, Lihua Yang, MD PhD, Hong Wen

Blood (2019) 134 (Supplement_1): 2596.

https://doi.org/10.1182/blood-2019-128375

Published: 2019

Journal Articles

Acute Leukemia with Lineage Infidelity: Mixed Phenotype AML Exhibits a Distinct Immunophenotype with Clinical Features Overlapping Mixed Phenotype Acute Leukemia

Mindy P Kresch, BS, Wenbin Xiao, MD PhD, Kamal Menghrajani, MD, Christopher Famulare, MS, Minal A Patel, MPH, Jeeyeon Baik, Mikhail Roshal, MD PhD, Ross L. Levine, MD, Martin S. Tallman, MD, Jacob L Glass, MD PhD

Blood (2019) 134 (Supplement_1): 2718.

https://doi.org/10.1182/blood-2019-131104

Published: 2019

Journal Articles

A Multicenter Nonrandom Clinical Study Using Induction Regimen of FLAG-IDA or Dae in Treatment of 101 Children with Newly Diagnosed CBF-AML in South of China: Clinical Responses and the Midterm Report of Survival

Xiaoqin Feng, Jian Li, MD, Chunfu Li, MD, Mincui Zheng, Honggui Xu, Yingyi He, MD& PhD, Changgang Li, MD, Hong Wen, Xiangling He, Lihua Yang, MD PhD

Blood (2019) 134 (Supplement_1): 3857.

https://doi.org/10.1182/blood-2019-126863

Published: 2019

Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Blood (2019) 134 (Supplement_1): 3943.

https://doi.org/10.1182/blood-2019-128683

Published: 2019

Journal Articles

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Jonathan E. Kolitz, MD, Daniel H. Ryan, MD, Laura F. Newell, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Gary J. Schiller, MD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3856.

https://doi.org/10.1182/blood-2019-124553

Published: 2019

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Daniel H. Ryan, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Richard M. Stone, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3842.

https://doi.org/10.1182/blood-2019-124516

Published: 2019

Journal Articles

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Matthew Jenner, MBBS, MRCP, FRCPath, Amy L Sherborne, PhD, Andrew Hall, Vallari Shah, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, James Croft, MBBS, BSc, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Louise Flanagan, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Ruth M De Tute, BSc,MSc, Roger G. Owen, MD, Guy Pratt, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 3162.

https://doi.org/10.1182/blood-2019-123547

Published: 2019

Journal Articles

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Martin F. Kaiser, Matthew Jenner, MBBS, MRCP, FRCPath, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Andrea Paterson, Rebecca Mottram, BA, BSc, Faith E. Davies, MD, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Gareth Morgan, MDPhDFRCP, Gordon Cook, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD

Blood (2019) 134 (Supplement_1): 604.

https://doi.org/10.1182/blood-2019-124819

Published: 2019

Journal Articles

A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group

Blood (2019) 134 (Supplement_1): 648.

https://doi.org/10.1182/blood-2019-125053

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia

Treatment Outcome and a Practical 10-Point Prognostic Index in Adult Patients with Non-M3 Acute Myeloid Leukemia: A Retrospective, Multicenter Study in Malaysia

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

PKC-Epsilon Overexpression Is Associated with Poor Outcomes in AML and Promotes Chemoresistance and Hematopoietic Stem Cell Quiescence

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia

Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival

Effectiveness and Survival of 4 Courses of Chemotheray in 321 Children with Acute Myeloid Leukemia in China: A Multicenter, Nonrandomized Clinical Study

Acute Leukemia with Lineage Infidelity: Mixed Phenotype AML Exhibits a Distinct Immunophenotype with Clinical Features Overlapping Mixed Phenotype Acute Leukemia

A Multicenter Nonrandom Clinical Study Using Induction Regimen of FLAG-IDA or Dae in Treatment of 101 Children with Newly Diagnosed CBF-AML in South of China: Clinical Responses and the Midterm Report of Survival

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only